Completed PHASE3 INTERVENTIONAL 2-arm NCT02009865

Epanova® for Lowering Very High Triglycerides II (EVOLVE II) (EVOLVEII)

A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA™ in Subjects With Severe Hypertriglyceridemia (EVOLVE II)

Sponsor: AstraZeneca

Conditions Hypertriglyceridemia

Interventions Epanova Olive Oil

Updated 8 times since 2017 Last updated: Sep 2, 2019 Started: Dec 16, 2013 Primary completion: Dec 23, 2014 Completion: Dec 23, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Hypertriglyceridemia and is currently completed. AstraZeneca leads this study, which shows 8 recorded versions since 2013 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Oct 2019 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Oct 2019 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Dec 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Addison, United States , Alkmaar, Netherlands , Amsterdam, Netherlands , Baja, Hungary , Balatonfüred, Hungary , Barnaul, Russia , Bristol, United States , Budapest, Hungary , Chicoutimi, Canada , Cincinnati, United States and 27 more locations